These tumor responses motivated our investigation of the effects from genetic as well as pharmacologic inhibition of Axl and EGFR, either concurrent with the PLX4720 tool compound treatment or subsequent to BRAFV600E glioma adaptation to tool compound treatment. Here, EGFR is linked to glioma.